GlassScriptPhysician profile
Clete Anthony Kushida
NPI 1780741652
$57,961.53
in general payments reported to CMS, 2019-2025
12 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what 80% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $4,750 · 2021: $5,570 · 2022: $5,255 · 2023: $563 · 2024: $24K · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Travel and Lodging: $2,110 · Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,650.00 |
| Travel and Lodging | $2,109.65 |
| Food and Beverage | $358.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12,672.31 | 2019-2020 | |
| Alkermes, INC. | $12,380.86 | 2024 | |
| Eli Lilly and Company | $9,915.39 | 2024 | Mounjaro |
| Avadel Cns Pharmaceuticals, LLC | $7,644.39 | 2020-2025 | Lumryz |
| Eisai INC. | $5,130.00 | 2022 | |
| Genentech, INC. | $4,345.58 | 2019 | |
| Itamar Medical INC | $3,000.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $2,713.01 | 2021-2024 | |
| Kls-Martin L.P. | $125.00 | 2022 | |
| Lilly USA, LLC | $34.99 | 2024 | Zepbound |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clete Kushida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.